最新医学別冊　診断と治療のABC142　ウイルス性肝炎

出版社： 最新医学社
発行日： 2019-01-01
分野： 臨床医学：一般  >  雑誌
ISSN： 03708241
雑誌名：
特集： ウイルス性肝炎
電子書籍版： 2019-01-01
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

5,500 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

2,750 円(税込)

購入する
特記事項：
  • 「診断と治療のABC」シリーズは本号を以て休刊となります。

目次

  • 特集　ウイルス性肝炎

    序
    眼で見るウイルス性肝炎

    第１章　概念・疫学
    　ウイルス性肝炎の概念と分類
    　ウイルス性肝炎の疫学

    第２章　病理・病態生理
    　肝炎ウイルスの種類
    　ウイルス性肝炎の発症機構
    　ウイルス性肝炎の病理像と組織分類
    　肝炎ウイルス関連肝がんのがんゲノム変異と発がん機構
    　慢性肝炎・肝硬変の病態と自然経過

    第３章　診断
    　血液生化学検査，肝炎ウイルスマーカー
    　腫瘍マーカーと線維化・発がんリスクマーカー
    　画像所見：急性肝炎，慢性肝炎，肝硬変

    第４章　B型肝炎
    　B型急性肝炎の疫学・自然経過
    　B型慢性肝炎・肝硬変の自然経過と予後
    　治療ガイドライン
    　核酸アナログ薬
    　インターフェロン製剤
    　B型肝炎再活性化と対策
    　コラム：B型肝炎完全排除を目指した薬剤の開発状況

    第５章　C型肝炎
    　C型急性肝炎
    　C型肝炎と糖脂質代謝
    　治療ガイドライン
    　直接作用型抗ウイルス薬（DAA）による抗ウイルス療法
    　薬剤耐性変異と再治療
    　非代償性肝硬変の治療
    　ウイルス排除と肝発がんリスク
    　コラム：直接作用型抗ウイルス薬（DAA）治療とHBV再活性化

    第６章　 経口肝炎(A型、E型肝炎)
    　A型肝炎
    　E型肝炎

    第７章　肝疾患診療と行政、病診連携
    　ウイルス性肝炎・肝硬変診療に関連する社会保障制度
    　肝疾患診療連携拠点病院と地域的・全国的な肝炎診療連携ネットワーク
    　B型肝炎母子感染防止対策
    　コラム：ウイルス性肝炎の受検・受療に向けた取組み：肝炎医療コーディネーター

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 概念・疫学

P.17 掲載の参考文献
1) Henning K J, et al : A community-wide outbreak of hepatitis A : risk factors for infection among homosexual and bisexual men. Am J Med 99 : 132-136, 1995.
PubMed
2) Brown G R, et al : Hepatitis A epidemic in the elderly. South Med J 95 : 826-833, 2002.
PubMed
3) Chang M H, et al : Prospective study of asymptomatic HBsAg carrier children infected in the perinatal period : clinical and liver histologic studies. Hepatology 8 : 374-377, 1988.
PubMed
4) Lok A S, et al : A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children. Hepatology 8 : 1130-1133, 1988.
PubMed
5) Lok A S, et al : Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 92 : 1839-1843, 1987.
PubMed
6) Asahina Y, et al : JSH Guidelines for the Management of Hepatitis C Virus Infection : A 2016 update for genotype 1 and 2. Hepatol Res 46 : 129-165, 2016.
PubMed
7) Tanaka Y, et al : Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavhin therapy for chronic hepatitis C. Nat Genet 41 : 1105-1109, 2009.
PubMed
8) Tamada Y, et al : Consumption of wild boar linked to cases of hepatitis E. J Hepatol 40 : 869-870, 2004.
PubMed
9) Tei S, et al : Zoonotic transmission of hepatitis E virus from deer to human beings. Lancet 362 : 371-373, 2003.
PubMed
10) Inagaki Y, et al : A Nationwide Survey of Hepatitis E Virus Infection and Chronic Hepatitis E in Liver Transplant Recipients in Japan. EBioMedicine 2 : 1607-1612, 2015.
PubMed
P.26 掲載の参考文献
1) World Health Organization : Hepatitis C, Hepatitis B. (Global Alert and Response, 2002), World Health Organization, Geneva, 2002.
 
2) World Health Organization : Global hepatitis report. 2017.
 
3) The Polaris Obervatory HCV Collaborators : Global prevalance and genotype distribution of hepatitis C virus infection 2015 : a modelling study. Lancet Gastroenterol Hepatol 2 : 161-176, 2017.
 
4) Oza N, et al : Current activities and future directions of comprehensive hepatitis control measures in Japan : The supportive role of the Hepatitis Information Center in building a solid foundation. Hep Res 47 (6) : 487-496, 2017.
 
5) Tanaka J, et al : Trends in the total numbers of HBV and HCV carriers in Japan from 2000 to 2011. J Viral Hepat 25 (4) : 363-372, 2018.
PubMed
6) 厚生労働科学研究費補助金 肝炎等克服政策研究事業 平成26年度「急性感染も含めた肝炎ウイルス感染状況・長期経過と治療導入対策に関する研究」研究報告書. 2015.
 
7) <http://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou09/pdf/hourei-140331-4.pdf>
 
8) Tanaka J, et al : Sex- and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3,485,648 first-time blood donors during 1995-2000. Intervirology 47 : 32-40, 2004.
 
9) Tanaka J, et al : Total numbers of undiagnosed carriers of hepatitis C and B viruses in Japan estimated by age-and area-specific prevalence on the national scale. Intervirology 54 (4) : 185-195, 2011.
 
10) 相崎英樹 : 感染症サーベイランスの現状把握, 厚生労働科学研究費補助金 (肝炎等克服政策研究事業) 肝炎ウイルス感染状況と感染後の長期経過に関する研究 (代表 : 田中純子) 平成29年度分担研究報告書, p59-60. 2018.
 
11) 相崎英樹 : 1999年から2013年に感染症法に基づき届出された急性C型肝炎の疫学解析, 厚生労働科学研究費補助金 (肝炎等克服政策研究事業) 急性肝炎も含めた肝炎ウイルス感染状況・長期経過と治療導入対策に関する研究 (代表 : 田中純子) 平成26年度分担研究報告書, p55-58. 2015.
 
12) Uchida S, et al : Incidence rates of hepatitis C virus infection among blood donors in Japan : a nationwide retrospective cohort study. Transfusion (in press).
 
13) Tanaka J, et al : Incidence rates of hepatitis B and C virus infections among blood donors in Hiroshima, Japan, during 10 years from 1994 to 2004. Intervirology 51 (1) : 33-41, 2008.
 
14) 平成29年度厚生労働科学研究費補助金 肝炎等克服政策研究事業肝炎ウイルス感染状況と感染後の長期経過に関する研究総括・研究報告書 (田中純子), p207-222, 2018.
 

第2章 病理・病態生理

P.34 掲載の参考文献
1) 日本肝臓学会肝炎診療ガイドライン作成委員会編 : B型肝炎治療ガイドライン (第3版). 2017年8月.
 
2) 日本肝臓学会肝炎診療ガイドライン作成委員会編 : C型肝炎治療ガイドライン (第62版). 2018年10月.
 
3) 日本肝臓学会編 : 肝臓専門医テキスト (改訂第2版). 南江堂, 東京, 2016.
 
4) 新ウイルス性肝炎学 (最新の基礎・臨床研究情報). 日本臨床社, 大阪, 2015.
 
5) Huang C R, et al : Hepatitis D virus infection, replication and cross-talk with the hepatitis B virus. World J Gastroenterol 20 : 14589-14597, 2014.
PubMed
P.42 掲載の参考文献
1) Park S H, et al : Immune responses to HCV and other hepatitis viruses Immunity 40 : 13-24, 2014.
PubMed
2) Guidotti L G et al : Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 1 : 23-61, 2006.
PubMed
3) Walker C M, et al : Reassessing immune control of hepatitis A virus. Curr Opin Virol 11 : 7-13, 2015.
PubMed
4) Debing Y, et al : Update on hepatitis E virology : implications for clinical practice. J Hepatol 65 : 200-212, 2016.
PubMed
5) Schneider W M, et al : Interferon-stimulated genes : a complex web of host defenses. Annu Rev Immunol 32 : 513-545, 2014.
 
6) Horner S M, et al : Regulation of hepatic innate immunity by hepatitis C virus. Nat Med 19 : 879-888, 2013.
 
7) Hiet M S : Control of temporal activation of hepatitis C virus-induced interferon response by domain 20f nonstructural protein 5A. J Hepatol 63 : 829-837, 2015.
 
8) Arnaud N : Hepatitis C virus reveals a novel early control in acute immune response. PLoS Pathog 7 : e1002289, 2011.
PubMed
9) Li K : Activation of chemokine and inflammatory cytokine response in hepatitis C virus-infected hepatocytes depends on Toll-like receptor 3 sensing of hepatitis C virus double-stranded RNA intermediates. Hepatology 55 : 666-675, 2012.
PubMed
10) Schoggins J W : A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472 : 481-485, 2011.
PubMed
11) Horner S M, et al : Mitochondrial-associated endoplasmic reticulum membranes (MAM) form innate immune synapses and are targeted by hepatitis C virus. Proc Natl Acad Sci USA 108 : 14590-14595, 2011.
PubMed
12) Bender S : Activation of type I and III interferon response by mitochondrial and peroxisomal MAVS and inhibition by hepatitis C virus. PLoS Pathog 11 : e1005264, 2015.
PubMed
13) Bellecave P : Cleavage of mitochondrial antiviral signaling protein in the liver of patients with chronic hepatitis C correlates with a reduced activation of the endogenous interferon system. Hepatology 51 : 1127-1136, 2010.
PubMed
14) Li K : Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci USA 102 : 2992-2997, 2005.
PubMed
15) Wieland S : Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver. Hepatology 59 : 2121-2130, 2014.
PubMed
16) Israelow B, et al : HepG2 cells mount an effective antiviral interferon-lambda based innate immune response to hepatitis C virus infection. Hepatology 60 : 1170-1179, 2014.
PubMed
17) Park H : IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection. Hepatology 56 : 2060-2070, 2012.
 
18) Sheahan T : Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness. Cell Host Microbe 15 : 190-202, 2014.
PubMed
19) Dreux M : Short-range exosomal transfer of viral RNA from infected cells to plasmacytoid dendritic cells triggers innate immunity. Cell Host Microbe 12 : 558-570, 2012.
PubMed
20) Sung P S : Roles of unphosphorylated ISGF3 in HCV infection and interferon responsiveness. Proc Natl Acad Sci USA 112 : 10443-10448, 2015.
PubMed
21) Cheon H : IFNβ-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage. Embo J 32 : 2751-2763, 2013.
 
22) Chen L : Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 128 : 1437-1444, 2005.
PubMed
23) Feld J J : Hepatic gene expression during treatment with peginterferon and ribavirin : identifying molecular pathways for treatment response. Hepatology 46 : 1548-1563, 2007.
PubMed
24) Dill M T : Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 140 : 1021-1031, 2011.
PubMed
25) Randall G : Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection. Gastroenterology 131 : 1584-1591, 2006.
PubMed
26) Feng Q, et al : Induction and suppression of innate antiviral responses by picornaviruses. Cytokine Growth Factor Rev 25 : 577-585, 2014.
PubMed
27) Yang Y : Disruption of innate immunity due to mitochondrial targeting of a picornaviral protease precursor. Proc Natl Acad Sci U S A 104 : 7253-7258, 2007.
PubMed
28) Qu L : Disruption of TLR3 signaling due to cleavage of TRIF by the hepatitis A virus protease-polymerase processing intermediate, 3CD. PLoS Pathog 7 : e1002169, 2011.
PubMed
29) Wang D : Hepatitis A virus 3C protease cleaves NEMO to impair induction of beta interferon.　J Virol 88 : 10252-10258, 2014.
PubMed
30) Feng Z : Human pDCs preferentially sense enveloped hepatitis A virions. J Clin Invest 125 : 169-176, 2015.
PubMed
31) Feng Z : A pathogenic picornavirus acquires an envelope by hijacking cellular membranes. Nature 496 : 367-371, 2013.
 
32) Wieland S, et al : Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci USA 101 : 6669-6674, 2004.
PubMed
33) Sato S : The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus. Immunity 42 : 123-132, 2015.
PubMed
34) Lu H L, et al : Melanoma differentiation-associated gene 5 senses hepatitis B virus and activates innate immune signaling to suppress virus replication. J Immunol 191 : 3264-3276, 2013.
PubMed
35) Wang H, et al : Hepatitis B virus polymerase blocks pattern recognition receptor signaling via interaction with DDX 3 : implications for immune evasion. PLoS Pathog 6 : e1000986, 2010.
 
36) Liu Y H : Hepatitis B virus polymerase disrupts K63-linked ubiquitination of STING to block innate cytosolic DNA-sensing pathways. J Virol 89 : 2287-2300, 2015.
 
37) Chen J L : Hepatitis B virus polymerase impairs interferon-α-induced STAT activation through inhibition of importin-α5 and protein kinase C-δ. Hepatology 57 : 470-482, 2013.
 
38) Wei C : The hepatitis B virus X protein disrupts innate immunity by downregulating mitochondrial antiviral signaling protein. J Immunol 185 : 1158-1168, 2010.
 
39) Lutgehetmann M : Hepatitis B virus limits response of human hepatocytes to interferon-α in chimeric mice. Gastroenterology 140 : 2074-2083, 2011.
 
40) Devhare P B, et al : Analysis of antiviral response in human epithelial cells infected with hepatitis E virus. PLoS One 8 : e63793, 2013.
PubMed
41) Nan Y, et al : Enhancement of interferon induction by ORF3 product of hepatitis E virus. J Virol 88 : 8696-8705, 2014.
PubMed
42) Xu L, et al : RIG-I is a key antiviral interferon-stimulated gene against hepatitis E virus regardless of interferon production. Hepatology 65 : 1823-1839, 2017.
PubMed
43) Sayed I M, et al : Study of hepatitis E virus infection of genotype　1 and 3 in mice with humanised liver. Gut 66 : 920-929, 2017.
PubMed
44) Moal V, et al : Chronic hepatitis E virus infection is specifically associated with an interferon-related transcriptional program. J Infect Dis 207 : 125-132, 2013.
 
45) Yu C, et al : Pathogenesis of hepatitis E virus and hepatitis C virus in chimpanzees : similarities and diliferences. J Virol 84 : 11264-11278, 2010.
PubMed
46) Shoukry N H : Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 197 : 1645-1655, 2003.
PubMed
47) Grakoui A : HCV persistence and immune evasion in the absence of memory T cell help. Science 302 : 659-662, 2003.
PubMed
48) Thimme R : CD8+ T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 77 : 68-76, 2003.
PubMed
49) Thimme R : Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci U S A 99 : 15661-15668, 2002.
PubMed
50) Shin E C : Delayed induction, not impaired recruitment, of specific CD8+ T cells causes the late onset of acute hepatitis C. Gastroenterology 141 : 686-695, 2011.
 
51) Shin E C : Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection. J Clin Invest 116 : 3006-3014, 2006.
PubMed
52) Sung P S, et al : CD8+ T-Cell responses in acute hepatitis C virus infection. Front Immunol 5 : 266, 2014.
PubMed
53) Lechner F : Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 191 : 1499-1512, 2000.
PubMed
54) Thimme R : Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 194 : 1395-1406, 2001.
PubMed
55) Shin E C : The frequency of CD127+ hepatitis C virus (HCV) -specific T cells but not the expression of exhaustion markers predicts the outcome of acute HCV infection. J Virol 87 : 4772-4777, 2013.
PubMed
56) Bowen D G, et al : Mutational escape from CD8+ T cell immunity : HCV evolution, from chimpanzees to man. J Exp Med 201 : 1709-1714, 2005.
 
57) Semmo N : Preferential loss of IL-2-secreting CD4+ T helper cells in chronic HCV infection. Hepatology 41 : 1019-1028, 2005.
PubMed
58) Schulze Zur Wiesch J : Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence. J Exp Med 209 : 61-75, 2012.
PubMed
59) Raziorrouh B : Virus-specific CD4+ T cells have functional and phenotypic characteristics of follicular T-Helper cells in patients with acute and chronic HCV infections. Gastroenterology 150 : 696-706, 2016.
PubMed
60) Perrella A : Elevated CD4+/CD25+ T cell frequency and function during acute hepatitis C presage chronic evolution. Gut 55 : 1370-1371, 2006.
PubMed
61) Smyk-Pearson S : Functional suppression by FoxP3+CD4+CD25high regulatory T cells during acute hepatitis C virus infection. J Infect Dis 197 : 46-57, 2008.
PubMed
62) Heeg M H : FOXP3 expression in hepatitis C virus-specific CD4+ T cells during acute hepatitis C. Gastroenterology 137 : 1280-1288, 2009.
PubMed
63) Kared H, et al : Galectin-9 and IL-21 mediate cross-regulation between Th17 and Treg cells during acute hepatitis C. PLoS Pathog 9 : e1003422, 2013.
PubMed
64) Chisari F V, et al : Pathogenesis of hepatitis B virus infection. Pathol Biol 58 : 258-266, 2010.
PubMed
65) Rehermann B : The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 181 : 1047-1058, 1995.
PubMed
66) Kefalakes H : Adaptation of the hepatitis B virus core protein to CD8+ T-cell selection pressure. Hepatology 62 : 47-56, 2015,
PubMed
67) Rehermann B, et al : Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 5 : 215-229, 2005.
PubMed
68) Asabe S : The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol 83 : 9652-9662, 2009.
 
69) Schulte I : Characterization of CD8+ T-cell response in acute and resolved hepatitis A virus infection. J Hepatol 54 : 201-208, 2011.
PubMed
70) Zhou Y : Dominance of the CD4+ T helper cell response during acute resolving hepatitis A virus infection. J Exp Med 209 : 1481-1492, 2012.
PubMed
71) Choi Y S : Liver injury in acute hepatitis A is associated with decreased frequency of regulatory T cells caused by Fas-mediated apoptosis. Gut 64 : 1303-1313, 2015.
PubMed
72) Manangeeswaran M : Binding of hepatitis A virus to its cellular receptor 1 inhibits T-regulatory cell functions in humans. Gastroenterology 142 : 1516-1525, 2012.
PubMed
73) Nakamoto N : Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog 5 : e1000313, 2009.
PubMed
74) Golden-Mason L : Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J Virol 81 : 9249-9258, 2007.
PubMed
75) Golden-Mason L : Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. J Virol 83 : 9122-9130, 2009.
 
76) Schlaphoff V : Dual function of the NK cell receptor 2B4 (CD244) in the regulation of HCV-specific CD8+ T cells. PLoS Pathog 7 : e1002045, 2011.
PubMed
77) Bengsch B : Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog 6 : e1000947, 2010,
 
78) Gupta P K : CD39 expression identifies terminally exhausted CD8+ T cells. PLoS Pathog 11 : e1005177, 2015.
PubMed
79) Lee J, et al : T-cell dysfunction and inhibitory receptors in hepatitis C virus infection. Immune Netw 10 : 120-125, 2010.
 
80) McMahan R H : Tim-3 expression on PD-1+HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J Clin Invest 120 : 4546-4557, 2010.
PubMed
81) Kroy D C : Liver environment and HCV replication affect human T-cell phenotype and expression of inhibitory receptors. Gastroenterology 146 : 550-561, 2014.
 
82) Radziewicz H : Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J Virol 81 : 2545-2553, 2007.
PubMed
83) Owusu Sekyere S : A heterogeneous hierarchy of co-regulatory receptors regulates exhaustion of HCV-specific CD8 T cells in patients with chronic hepatitis C. J Hepatol 62 : 31-40, 2015.
PubMed
84) Fuller M J : Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). Proc Natl Acad Sci USA 110 : 15001-15006, 2013.
PubMed
85) Gardiner D : A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PLoS One 8 : e63818, 2013.
 
86) Bengsch B, et al : Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation. J Hepatol 61 : 1212-1219, 2014.
 
87) Fisicaro P : Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 138 : 682-693, 2010.
PubMed
88) Schurich A : Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection. Hepatology 53 : 1494-1503, 2011.
PubMed
89) Nebbia G : Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection. PLoS One 7 : e47648, 2012.
PubMed
90) Raziorrouh B : The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus-specific CD8+ T-cell function. Hepatology 52 : 1934-1947, 2010.
PubMed
91) Boni C : Characterization of hepatitis B virus (HBV) -specific T-cell dysfunction in chronic HBV infection. J Virol 81 : 4215-4225, 2007.
PubMed
92) Fisicaro P : Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV. Gastroenterology 143 : 1576-1585, 2012.
 
93) Kurktschiev P D : Dysfunctional CD8+ T cells in hepatitis B and C are characterized by a lack of antigen-specific T-bet induction. J Exp Med 211 : 2047-2059, 2014.
 
94) Lopes A R : Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection. J Clin invest 118 : 1835-1845, 2008.
PubMed
95) Peppa D : Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. J Exp Med 210 : 99-114, 2013.
PubMed
96) Cabrera R : An immunomodulatory role for CD4+ CD25+ regulatory T lymphocytes in hepatitis C virus infection. Hepatology 40 : 1062-1071, 2004.
PubMed
97) Claassen M A, et al : Abundant numbers of regulatory T cells localize to the liver of chronic hepatitis C infected patients and limit the extent of fibrosis. J Hepatol 52 : 315-321, 2010.
 
98) Stoop J N : Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 41 : 771-778, 2005.
 
99) Park J J : Hepatitis B virus-specific and global T-Cell dysfunction in chronic hepatitis B. Gastroenterology 150 : 684-695, 2016.
PubMed
100) Boettler T : Tcells with a CD4+ CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. J Virol 79 : 7860-7867, 2005.
PubMed
101) Franceschini D : PD-L1 negatively regulates CD4+CD25+Foxp3+ T regs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J Clin Invest 119 : 551-564, 2009.
 
P.56 掲載の参考文献
1) Neil D. Theise N D, et al : 6-Viral Hepatitis. In : Macsween's Pathology of the Liver (7th edition). p372-415, Science Direct 2018.
 
2) 市田文弘, 他 : 慢性肝炎の肝組織診断基準-新犬山分類. 中外医学社, 東京, 1996.
 
3) Bedossa P, et al : An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24 : 289-293, 1996.
 
4) Tsochatzis E A, et al : Liver cirrhosis. Lancet 383 : 1749-1761, 2014.
PubMed
5) Abe T, et al : Quantification of collagen and elastic fibers using whole-slide images of liver biopsy specimens. Pathol Int 63 : 305-310, 2013.
PubMed
6) Yasui Y, et al : Elastin Fiber Accumulation in Liver Correlates with the Development of Hepatocellular Carcinoma. PLoS One 11 : e0154558, 2016.
PubMed
7) Poynard T, et al : Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122 : 1303-1313, 2002.
PubMed
8) George S L, et al : Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy : a 5-year follow-up of 150 patients. Hepatology 49 : 729-738, 2009.
PubMed
9) Issa R, et al : Apoptosis of hepatic stellate cells : involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut 48 : 548-557, 2001.
PubMed
10) Akhtar E, et al : Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy : a meta-analysis. Liver Int 35 : 30-36, 2015.
PubMed
11) Calvaruso V, et al : Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. Gastroenterology 155 : 411-421, e414, 2018.
 
12) Reig M, et al : Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 65 : 719-726, 2016.
PubMed
P.65 掲載の参考文献
1) Fujimoto A, et al : Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet 44 : 760-764, 2012.
PubMed
2) Totoki Y, et al : Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet 46 : 1267-1273, 2014.
PubMed
3) Fujimoto A, et al : Whole-genome mutational landscape and characterizatiorl of noncoding and structural mutations in liver cancer. Nat Genet 48 : 500-509, 2016.
PubMed
4) Li M, et al : Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet 43 : 828-829, 2011.
PubMed
5) Guichard C, et al : Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 44 : 694-698, 2012.
PubMed
6) Huang F W, et al : Highly recurrent TERT promoter mutations in human melanoma. Science 339 : 957-959, 2013.
PubMed
7) Horn S, et al : TERT promoter mutations in familial and sporadic melanoma. Science 339 : 959-961, 2013.
PubMed
8) Killela P J, et al : TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 110 : 6021-6026, 2013.
 
9) Nault J C, et al : High frequency of teiomerase reverse-transcrlptase promoter somatlc mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun 4 : 2218, 2013.
PubMed
10) Fujimoto A, et al : Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. Nat Genet 48 : 500-509, 2016.
PubMed
11) Nault J C, et al : Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology 60 : 1983-1992, 2014.
PubMed
12) Schulze K, et al : Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet 47 : 505-511, 2015.
PubMed
13) Kawai-Kitahata F, et al : Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features. J Gastroenterol 51 : 473-486, 2016.
PubMed
14) Kim C M, et al : HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 351 : 317-320, 1991.
PubMed
15) Brechot C, et al : Presence of integrated hepatitis B Virus DNA sequences in cellUlar DNA of human hepatocellular carcinoma. Nature 286 : 533-535, 1980.
PubMed
16) Neuveut C, et al : Mechanisms of HBV-related hepatocarcinogenesis. J Hepatol 52 : 594-604, 2010.
PubMed
17) Sung W K, et al : Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma Nat Genet 44 : 765-769, 2012.
PubMed
18) Moriya K, et al : The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 4 : 1065-1067, 1998.
PubMed
19) Nault J C, et al : Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet 47 : 1187-1193, 2015.
PubMed
20) Nagata H, et al : Effect of interferon-based and-free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J Hepatol 67 : 933-939, 2017.
 
P.71 掲載の参考文献
1) Guidotti L G, et al : Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol Mech Dis 1 : 23-61, 2006.
 
2) Iannacone M, et al : HBV pathogenesis in animal models : recent advances on the role of platelets. J Hepatol 46 : 19-26, 2007.
 
3) Rehermann B : Hepatitis C virus versus innate and adaptive immune responses : a tale of coevolution and coexistence. J Clin Invest 119 : 1745-1757, 2009.
PubMed
4) Tutteleman J S, et al : Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 47 : 451-460, 1986.
 
5) Xu L, et al : Kupffer cell-derived IL-10 plays a key role in maintaining humoral immune tolerance in hepatitis B virus-persistent mice. Hepatology 59 : 443-452, 2014.
 
6) Zhang Z, et al : Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients. Hepatology 53 : 73-85, 2011.
PubMed
7) 日本肝臓学会肝炎診療ガイドライン作成委員会編 : B型肝炎治療ガイドライン第3版. 2017.
 
8) Lin S M, et al : Interferon therapy in HbeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 46 : 45-52, 2007.
PubMed
9) Hosaka T, et al : Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 58 : 98-107, 2013.
PubMed
10) Dustin L B : Innate and Adaptive Immune Responses in Chronic HCV Infection. Curr Drug Targets 18 : 826-843, 2017.
PubMed
11) Bukh J : The history of hepatitis C virus (HCV) : Basic research reveals unique features in phylogeny, evolution and viral life cycle with new perspectives for epidemic control. J Hepatol 65 : S2-S21, 2016.
PubMed
12) Tada T, et al : Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. J Gastroenterol Hepatol 32 : 1982-1988, 2017.
PubMed
13) Curry M P, et al : Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med 373 : 2618-2628, 2015.
PubMed
14) Nagata H, et al : Effect of interferon-based and-free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J Hepaol 67 : 933-939, 2017.
 
15) Llach J, et al : Prognostic value of arterial pressure, endogeneous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites, Gastroenterology 94 : 482-487, 1988.
 

第3章 診断

P.79 掲載の参考文献
1) Chen C J, et al : Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 : 65-73, 2006.
PubMed
2) Tseng T C, et al : High levels of hepatitis B surface antigen irlcrease risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 142 : 1140-1149, 2012.
PubMed
3) 田中靖人 : B型肝炎ウイルスコア関連抗原 (HBcrAg) 測定法の基礎的・臨床的検討. モダンメディア 54 (12) : 347-352, 2008.
 
4) Rokuhara A, et al : Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen : a marker distinct from viral DNA for monitoring lamivudine treatment. J Viral Hepat 10 : 324-330, 2003.
PubMed
5) Takahashi M, et al : Simultaneous detection of immunoglobulin A (IgA) and IgM antibodies against hepatitis E virus (HEV) Is highly specific for diagnosis of acute HEV infection. J Clin Microbiol 43 : 49-56, 2005.
PubMed
P.87 掲載の参考文献
1) 日本肝臓学会 : 肝癌診療ガイドライン2017年版. 2017.
 
2) Ishii M, et al : Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. Am J Gastroenterol 95 : 1036-1040, 2000.
 
3) Nakamura S, et al : Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol 101 : 2038-2043, 2006.
PubMed
4) Sterling R K, et al : Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma Clin Gastroenterol Hepatol 7 : 104-113, 2009.
PubMed
5) Kumada T, et al : High-sensitivity Lens culinaris agglutinin-reactive aipha-fetoprotein assay predicts early detection of hepatocellular carcinoma. J Gastroenterol 49 : 555-563, 2014.
 
6) 日本肝臓学会 : B型肝炎治療ガイドライン. 2017.
Medical*Online
7) 日本肝臓学会 : C型肝炎治療ガイドライン. 2018.
 
8) 泉並木, 他編 : 肝疾患診療に役立つ肝線維化評価テキスト. 文光堂, 東京, 2017.
 
9) Ito K, et al : LecT-Hepa, a glyco-marker derived from multiple lectins, as a predictor of liver fibrosis in chronic hepatitis C patients. Hepatology 56 : 1448-1456, 2012.
 
10) Yamasaki K, et al : Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding Protein predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology 60 : 1563-1570, 2014.
PubMed
11) Sasaki R, et al : Serum Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein Values Predict the Development of Hepatocellular Carcinoma among Patients with Chronic Hepatitis C after Sustained Virological Response. PLoS One 10 : e0129053, 2015.
PubMed
12) Nagata H, et al : Effect of interferon-based and-free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J Hepatol 67 : 933-939, 2017.
 
13) Poynard T, et al : Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 349 : 825-832, 1997.
PubMed
14) Shiratori Y, et al : Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Int Med 132 : 517-524, 2000.
PubMed
15) Asahina Y, et al : Effect of Aging on Risk for Hepatocellular Carcinoma in Chronic Hepatitis C Virus Infection. Hepatology 52 : 518-527, 2010.
PubMed
16) Oze T, et al : Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy. Clin Gastroenterol Hepatol 12 : 1186-1195, 2014.
 
17) Toyoda H, et al : Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection. J Gastroenterol Hepatol 30 : 1183-1189, 2015.
PubMed
18) Tachi Y, et al : Progressive fibrosis significantly correlates with hepatocellular carcinoma in patients with a sustained virological response. Hepatol Res 45 : 238-246, 2015.
PubMed
19) Reig M, et al : Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 65 : 719-726, 2016.
PubMed
20) Nahon P, et al : Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications. Gastroenterology 152 : 142-156. e142, 2017.
 
P.94 掲載の参考文献
1) Kumada T, et al : Characteristics of elderly hepatitis C virus-associated hepatocellular carcinoma patients. J Gastroenterol Hepatol 28 : 357-364, 2013.
PubMed
2) Morisaka H, et al : Magnetic resonance elastography is as accurate as liver biopsy for liver fibrosis staging. J Magn Reson Imaging 47 : 1268-1275, 2018.
PubMed

第4章 B型肝炎

P.100 掲載の参考文献
1) Yotsuyanagi H, et al : Risk Factors for Long-Term Persistence of Serum Hepatitis B Surface Antigen Following Acute Hepatitis B Virus Infection in Japanese Adults. Hepatology 59 (1) : 89-97, 2014.
PubMed
2) Ozasa A, et al : Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology 44 (2) : 326-334, 2006.
PubMed
3) Tamada Y, et al : Hepatitis B virus strains of subgenotype A2 with an identical sequence spreading rapidly from the capital region to all over Japan in patients with acute hepatitis B. Gut 61 (5) : 765-773, 2012.
PubMed
4) 国立感染症研究所 : 感染症発生動向調査年別報告数一覧 (全数把握 五類) -2016-. <https://www.niid.go.jp/niid/ja/survei/2085-idwr/ydata/7312-report-ja2016-30.html>
 
5) Sako A, et al : Acute hepatitis B in Japan : Incidence, clinical practices and health policy. Hepatol Res 41 (1) : 39-45, 2011.
PubMed
6) 山田典栄, 他 : 首都圏におけるB型急性肝炎の実態と変遷GenotypeAに焦点をあてて. 肝臓 49 (12) : 553-559, 2008.
 
7) Yotsuyanagi H, et al : Geographic distribution and characteristics of genotype A hepatitis B virus infection in acute and chronic hepatitis B patients in Japan. J Gastroenterol Hepatol 31 (1) : 180-189, 2016.
PubMed
8) Matsuura K, et al : Distribution of hepatitis B virus genotypes among patients with chronic infection in Japan shifting toward an increase of genotype A. J Clin Microbiol 47 (5) : 1476-1483, 2009.
 
9) 吉澤浩二, 他 : ウイルス肝炎 診断/予防/治療第2版. p21. 文光堂, 東京, 2002.
 
10) Kobayashi M, et al : Viral genotypes and response to interferon in patients with acute prolonged hepatitis B virus infection of adulthood in Japan. J Med Virol 68 : (4) 522-528, 2002.
PubMed
11) Koike K, et al : Prevalence of hepatitis B virus infection in Japanese patients with HIV. Hepatol Res 38 (3) : 310-314, 2008.
PubMed
12) Fujisaki S, et al : Outbreak of infections by hepatitis B virus genotype A and transmission of genetic drug resistance in patients coinfected with HIV-1 in Japan. J Clin Microbiol 49 (3) : 1017-1024, 2011.
PubMed
13) Bodsworth N J, et al : The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 163 (5) : 1138-1140, 1991.
PubMed
P.107 掲載の参考文献
1) Marusawa H, et al : Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology 31 : 488-495, 2000.
PubMed
2) 田中純子, 他 : 我が国におけるB型肝炎の疫学-国際比較を含めて. 日臨 69 : 327-334, 2011.
Medical*Online
3) Adkins B, et al : Neonatal adaptive immunity comes of age. Nat Rev Immunol 4 : 553-564, 2004.
PubMed
4) Hong M, et al : Tolerance and immunity to pathogens in early life : insights from HBV infection. Semin Immtlnopathol 39 : 643-652, 2017.
PubMed
5) Milich D, et al : Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology 38 : 1075-1086, 2003.
PubMed
6) Lin C L, et al : Natural history of acute and chronic hepatitis B : the roles of HBV genotypes and mutants. Best Prac Res Clin Gastroenterol 31 : 249-255, 2017.
 
7) Ito K, et al : Risk factors for long-term persistence of serum HBs antigen following acute B virus infection in Japanese adults. Hepatology 59 : 89-97, 2014.
 
8) McMahon J : The natural history of chronic hepatitis B virus infection, Hepatology 49 : S45-S55, 2009.
 
9) Szpakowski J L, et al : Causes of death in patients with hepatitis B : a natural history cohort study in the United States. Hepatology 58 : 21-30, 2013.
PubMed
10) Iloeje U, et al : Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 : 65-73, 2006.
PubMed
11) lloeje U H, et al : Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130 : 678-686, 2006.
 
12) Kimura T, et al : Hepatitis B virus DNA-negative dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain. J Biol Chem 280 : 21713-21719, 2005.
PubMed
13) 田中靖人, 他 : B型肝炎ウイルスコア関連抗原 (HBcrAg) 測定法の基礎的・臨床的検討, モダンメディア 54 : 347-352, 2008.
 
14) Rokuhara A, et al : Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen ; a marker distinct from viral DNA for monitoring lamivudine treatment. J Viral Hepat 10 : 324-330, 2003.
PubMed
15) Ando Y, et al : Cumulative incidence and risk factors for the development of hepatocellular carcinoma in patients with chronic hepatitis B who achieved sustained disappearance of viremia by nucleos (t) ide analog treatment. Hepatol Res 48 : E240-E251, 2018.
PubMed
P.117 掲載の参考文献
1) Chang M H, et al : Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Eng J Med 336 (26) : 1855-1859, 1997.
 
2) 日本肝臓学会, 肝炎診療ガイドライン作成委員会編 : B型肝炎治療ガイドライン (第3版). 2017.
 
3) Liaw Y F, et al : Lamivudine for patients with chronic hepatitis B and advanced liver disease. New Engl J Med 351 : 1521-1531, 2004.
PubMed
4) Yokosuka O, et al : Long-term use of entecavir in nucleoside-naive Japanese patients with chronic hepatitis B infection. J Hepatol 52 : 791-799, 2010.
PubMed
5) Chang T T, et al : Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B, Hepatology 52 : 886-893, 2010.
PubMed
6) Shim J H, et al : Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 52 : 176-182, 2010.
PubMed
7) Liaw Y F, et al : Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation : a randomized, open-label study. Hepatology 54 : 91-100, 2011.
PubMed
8) Matsumoto A, et al : Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B : A multicenter retrospective study of 2795 patients. Hepatol Res 32 : 173-184, 2005.
PubMed
9) Sung J J, et al : Meta-analysis : Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 28 : 1067-1077, 2008.
PubMed
10) Hosaka T, et al : Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 58 : 98-107, 2013.
PubMed
11) Wong G L, et al : Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 58 : 1537-1547, 2013.
PubMed
P.130 掲載の参考文献
1) Yatsuji H, et al : Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy : two-year follow-up. J Hepatol 48 : 923-931, 2008.
PubMed
2) Ono A, et al : Long-term continuous entecavir therapy in nucleos (t) ide-naive chronic hepatitis Bpatients. J Hepatol 57 : 508-514, 2012.
 
3) Suzuki F, et al : Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs. J Gastroenterol 52 : 641-651, 2017.
PubMed
4) Kumada H, et al : Efficacy and safety of tenofovir disoproxil fumarate rescue therapy for chronic hepatitis B patients who failed other nucleos (t) ide analogs. Hepatol Res 47 : 1032-1041, 2017.
PubMed
5) Koike K, et al : Randomized prospective study showing the non-inferiority of tenofovir to entecavir in treatment-naive chronic hepatitis B patient. Hepatol Res 48 : 59-68, 2018.
PubMed
6) Murakami E, et aHmplications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy. Antimicrob Agents Chemother 59 : 3563-3569, 2015.
 
7) Agarwal K, et al : Twenty-eight day safety, anti-viral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. J Hepatol 62 : 533-540, 2015.
 
8) Suzuki F, et al : Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine. J Gastroenterol 49 : 1094-1104, 2014.
PubMed
9) Suzuki F, et al : Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients. J Gastroenterol Hepatol 25 : 892-898, 2010.
PubMed
10) 日本肝臓学会肝炎診療ガイドライン作成委員会 : B型肝炎治療ガイドライン (第3版). 2017.
 
11) Hosaka T, et al : Clearance of hepatitis B surface antigen during long-term nucleot (s) ide analog treatment in chronic hepatitis B : results from a nine-year longitudinal study. J Gastroenterol 48 : 930-941, 2013.
PubMed
12) Hara T, et al : Long-term entecavir therapy results in falls in serum hepatitis B surface antigen levels and seroclearance in nucleos (t) ide-naive chronic hepatitis B patients. J Viral Hepat 21 : 802-808, 2014.
PubMed
13) Suzuki F, et al : Long-term outcome of entecavir treatment of nucleos (t) ide analogue-naive chronic hepatitis B patients in Japan. J Gastroenterol 2018 [Epub ahead of print].
 
14) Agarwal K, et al : 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol 68 : 672-681, 2018.
PubMed
15) Buti M, et al : Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection : a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 1 : 196-206, 2016.
PubMed
16) Matsumoto A, et al : Combinational use of hepatitis B viral antigens predicts responses to nucleos (t) ide analogue/peg-interferon sequential therapy. J Gastroenterol 53 : 247-257, 2018,
PubMed
17) Bourliere M, et al : Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos (t) ide analogue therapy versus nucleos (t) ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA : a randomised, controlled, open-label trial. Lancet Gastroenterol Hepatol 2 : 177-188, 2017.
PubMed
18) Fontana R J : Side effects of long-term oral anti-viral therapy for hepatitis B. Hepatology 49 (Suppl 5) : 185-195, 2009.
 
19) Lampertico P, et al : Review article : long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patient. Aliment Pharmacol Ther 44 : 16-34, 2016.
PubMed
20) Tanaka M, et al : Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B. J Gastroenterol 49 : 470-480, 2014.
PubMed
21) Hiramatsu R, et al : Bone histology of two Cases with osteomalacia related to low-dose adefovir. Intern Med 55 : 3013-3019, 2016.
PubMed
22) Liaw Y F, et al : Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 : 1521-1531, 2004.
PubMed
23) Hosaka T, et al : Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 58 : 98-107, 2013.
PubMed
24) Hosaka T, et al : Combined hepatitis B core-related antigen and surface antigen levels predict hepatocellular carcinoma development in patients treated with nucleos (t) ide analogues. Hepatology 62 (suppl) : 1193A, 2015.
 
P.139 掲載の参考文献
1) 肝炎ガイドライン作成委員会 : B型肝炎治療ガイドライン (第3版). 日本肝臓学会, 2017.
 
2) Croagh M N C, et al : Genotypes and viral variants in chronic hepatitis B : A review of epidemiology and clinical relevance. World J Hepatol 7 : 289-303, 2015.
 
3) Li W C, et al : Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion : a meta-analysis of controlled clinical trials. BMC Infect Dis 11 : 165-177, 2011.
PubMed
4) Martinot-Peignoux M, et al : Baseline HBeAg and HBcrAg titres allow peginterferon-based 'precision medicine' in HBeAg-negative chronic hepatitis B patients. J Viral Hepat 23 : 905-911, 2016.
PubMed
5) Matsumoto A, et al : Combination of hepatitis B viral antigens and DNA for prediction of relaps after discontinuation of nucleos (t) ide analog in patients with chronic hepatitis B. Hepatol Res 42 : 139-149, 2012.
 
6) Tanaka E, et al : Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis B. Hepatol Res 44 : 818-824, 2014.
 
7) Serfaty L, et al : sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone : results of a pilot study. Hepatology 34 : 573-577, 2001.
 
8) Matsumoto A, et al : Combinational use of hepatitis B viral antigens predicts responses to ucleos (t) ide analogue/peg-interferon sequential therap. J Gastroenterol 53 : 247-257, 2018.
 
9) Murata K, et al : Induction of IFN-λ3 as an addi-tional effect of nucleotide, not nucleoside, analogues : a new potential target for HBV infection.　GUT 67 : 362-371, 2018.
 
10) Marcellin P, et al : Combination of tenofovir Disoproxil fumarate and peginterferon a-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastrenterology 150 : 134-144, 2016.
 
11) Marcellin P, et al : Predictors of response to tenofovir disproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B. Aliment Pharmacol THer 44 : 957-966, 2016.
 
P.148 掲載の参考文献
1) 日本肝臓学会肝炎診療ガイドラン作成委員会編 : B型肝炎治療ガイドライン (第3版). 2017年8月 <https://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_b>
 
2) 坪内博仁, 他 : 免疫抑制・化学療法により発症するB型肝炎対策 : 厚生労働省「難治性の肝・胆道疾患に関する調査研究」班劇症肝炎分科会および「肝硬変を含めたウイルス性肝疾患の治療標準化に関する研究」班合同報告. 肝臓 50 : 38-42, 2009.
 
3) Mochida S, et al : Nationwide prospective and retrospective surveys for hepatitis B virus reactivation during immunosuppressive therapies. J Gastroenterol 51 : 999-1010, 2016.
PubMed
4) Nakao M, et al : Nationwide survey for acute liver failure and late-onset hepatic failure in Japan. J Gastroenterol 53 : 752-769, 2018.
PubMed
5) 持田智, 他 : 我が国における急性肝不全および遅発性肝不全 (LOHF) の実態 (2016年) : 平成29年度全国調査. 厚生労働省科学研究費補助金 (難治性疾患等政策研究事業) 「難治性の肝・胆道疾患に関する調査研究」平成29年度総括・分担研究報告書 p85-104, 2018.
 
6) Galbraith R M, et al : Fulminant hepatic failure in leukaemia and Nchoriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 2 : 528-530, 1975.
PubMed
7) Wands J R, et al : Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative
PubMed
8) Lok A S, et al : Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100 : 182-188, 1991.
PubMed
9) Kempinska A, et al : Reactivation of hepatitis B infection following allogeneic bone marrow transplantation in a hepatitis B-immune patient : case report and review of the literature. Clin Infect Dis 41 : 1277-1282, 2005.
 
10) Knoll A, et al : Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 33 : 925-929, 2004.
PubMed
11) 木村公則, 他 : 造血幹細胞移植後におけるB型肝炎ウイルス再活性化の実態および予防に関する多施設共同臨床研究. 固形がんにおけるB型肝炎ウイルス再活性化. 厚生労働科学研究費補助金肝炎等克服実用化研究事業 (肝炎等克服緊急対策事業), 「がん化学療法及び免疫抑制療法中のB型肝炎再活性化予防対策法の確立を目指したウイルス要因と宿主要因の包括的研究」班, 平成24～26年度総合研究報告書. P47-51, 2015.
 
12) Uemoto S, et al : Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation 65 : 494-499, 1998.
PubMed
13) Dervite I, et al : Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 344 : 68-69, 2001.
 
14) Kusumoto S, et al : Monitoring of Hepatitis B Virus (HBV) DNA and Risk of HBV Reactivation in B-Cell Lymphoma : A Prospective Observational Study. Clin Infect Dis 61 : 719-729, 2015.
 
15) 池田公史, 他 : 固形がんにおけるB型肝炎ウイルス再活性化厚生労働科学研究費補助金肝炎等克服実用化研究事業 (肝炎等克服緊急対策事業), 「がん化学療法及び免疫抑制療法中のB型肝炎再活性化予防対策法の確立を目指したウイルス要因と宿主要因の包括的研究」班, 平成24～26年度総合研究報告書. P31-34, 2015.
 
16) Takahashi H, et al : Multicenter cooperative case survey of hepatitis B virus reactivation by chemotherapeutic agents. Hepatol Res 45 : 1220-1227,　2015.
PubMed
17) Umemura T, et al : Fatal HBV reactivation in a　subject with anti-HBs and anti-HBc. Intern Med 45 : 747-748, 2006.
 
18) Fujiwara K, et al : Fulminant hepatitis and late onset hepatic failure in Japan. Hepatol Res 38 : 646-657, 2008.
PubMed
19) Oketani M, et al : Etiology and Prognosis of Fulminant Hepatitis and Late Onset Hepatic Failure in Japan : Summary of the Annual Nationwide Survey between 2004 and 2009. Hepatol Res 43 : 97-105, 2013.
PubMed
20) Hui C K, et al : Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 131 : 59-68, 2006.
PubMed
21) 持田智, 他 : 免疫抑制薬, 抗悪性腫瘍薬によるB型肝炎ウイルス再活性化の実態解明と対策法の確立」全体研究 (平成23年度). 厚生労働科学研究費補助金肝炎等克服緊急対策事業 (肝炎分野), 「免疫抑制薬, 抗悪性腫瘍薬によるB型肝炎再活性化の実態解明と対策法の確立」班, 平成23年度研究報告書 pp1-32, 2012.
 

第5章 C型肝炎

P.155 掲載の参考文献
1) Maheshwari A, et al : Acute hepatitis C. Lancet 26 : 321-322, 2008.
 
2) Tanaka E, et al : Natural history of acute hepatitis C J Gastroenterol Hepatol 15 : E97-104, 2000.
PubMed
3) Ge D, et al : Genetic variation in IL 28 B predicts hepatitis C treatmentinduced viral clearance. Nature 461 : 399-401, 2009.
 
4) Thomas D L, et al : Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461 : 798-801, 2009.
PubMed
5) Rauch A, et al : Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure : a genome-wide association study. Gastroenterology 138 : 1338-1345, 2010.
PubMed
6) 相崎英樹, 他 : わが国における急性ウイルス肝炎の動向. 医のあゆみ 262 : 1215-1220, 2017.
Medical*Online
7) 野村秀幸 : C型急性肝炎の治療IFN治療開始のタイミングは? 肝胆膵 57 : 925-929, 2008.
 
8) Nomura H, et al : Short-term interferon-alfa therapy for acute hepatitis C : arandomized controlled trial. Hepatology 39 : 1213-1219, 2004.
 
9) 八橋弘, 他 : C型肝炎 (インターフェロン, 化学療法). 臨と微生物 35 : 703-709, 2008.
Medical*Online
10) Kamal S M, et al : Peginterferon alfa-2b therapy in acute hepatitis C : impact of onset of therapy on sustained virologic response. Gastroenterology 130 : 632-638, 2016.
 
P.162 掲載の参考文献
1) Gill K, et al : Hepatitis C virus as a systemic disease : reaching beyond the liver. Hepatol Int 10 (3) : 415-423, 2016.
PubMed
2) Hui J M, et al : Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 125 : 1695-1704, 2003.
PubMed
3) Saito K, et al : Augmentation effect of postprandial hyperinsulinemia on growth of human hepatocellular carcinoma. Gut 51 : 100-104, 2002.
PubMed
4) Shintani Y, et al : Hepatitis C virus infection and diabetes : direct involvement of the virus in the development of insulin resistance. Gastroenterology 126 : 840-848, 2004.
PubMed
5) Alan R, et al : Insulin signalling and the regulation of glucose and Iipid metabolism. Nature 414 (6865) : 799-806, 2001.
 
6) Aytug S, et al : Impaired IRS-1_PI3-kinase signaling in patients with HCV : a mechanism for increased prevalence of type 2 diabetes.　Hepatology 38 : 1384-1392, 2003.
PubMed
7) Tsutsumi T, et al : Alteration of intrahepatic cytokine expression and AP-1 activation in transgenic mice expressing hepatitis C virus core protein. Virology 304 : 415-424, 2002.
PubMed
8) Kawaguchi T, et al : Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 165 : 1499-1508, 2004.
PubMed
9) Deng L, et al : Hepatitis C virus infection promotes hepatic gluconeogenesis through an NS5A-mediated, FoxO1-dependent pathway. J Virol 85 : 8556-8568, 2011.
PubMed
10) Matsui C, et al : Hepatitis C virus infection suppresses GLUT2 gene expression via downregulation of hepatocyte nuclear factor 1 alpha. J Virol 86 : 12903-12911, 2012.
PubMed
11) Hum J, et al : Improvement in Glycemic Control of Type 2 Diabetes After Successful Treatment of Hepatitis C Virus. Diabetes Care 40 (9) : 1173-1180, 2017.
PubMed
12) Nishimura N, et al : Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long-Evans Tokushima fatty rats. J Gastroenterol 51 (12) : 1141-1149, 2016.
PubMed
13) Bach N, et al : The histological features of chronic hepatitis C and autoimmune chronic hepatitis : a comparative analysis. Hepatology 15 : 572-577, 1992.
PubMed
14) Perlemuter G, et al : Hepatitis C virus core protein inhibits microsomal trigiyceride transfer protein activity and very low density lipoprotein secretion : a model of viralrelated steatosis. FASEB J 16 : 185-194, 2002.
 
15) Shimano H : Sterol regulatory element-binding protein family as global regulators of lipid synthetic genes in energy metabolism. Vitam Horm 65 : 167-194, 2002.
PubMed
16) Moriishi K, et al : Critical role of PA28gamma in hepatitis C virusassociated steatogenesis and hepatocarcinogenesis. Proc Natl Acad Sci U S A 104 : 1661-1666, 2007.
PubMed
17) Korenaga M, et al : Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J Biol Chem 280 : 37481-37488, 2005.
PubMed
18) Foretz M, et al : ADD1/SREBP-1c is required in the activation of hepatic lipogenic gene expression by glucose. Mol Cell Biol 19 (5) : 3760-3768, 1999.
 
19) Shimizu K, et al : Eradication of hepatitis C virus is associated with the attenuation of steatosis as evaluated using a controlled attenuation parameter. Sci Rep 8 (1) : 7845, 2018.
PubMed
20) Arase Y, et al : Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology 57 : 964-973, 2013.
PubMed
P.169 掲載の参考文献
1) Yamada I, et al : Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection. J Viral Hepat 19 : e112-119, 2012,
 
2) Toyota J, et al : Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b. J Viral Hepat 20 : 167-173, 2013.
PubMed
3) Chayama K, et al : Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 55 : 742-748, 2012.
PubMed
4) Suzuki Y, et al : Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 58 : 655-662, 2013.
PubMed
5) Kumada H, et al : Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 59 : 2083-2091, 2014.
PubMed
6) Kobayashi M, et al : Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection. J Med Virol 89 : 476-483, 2017.
PubMed
7) 日本肝臓学会, 肝炎診療ガイドライン作成委員会編 : C型肝炎治療ガイドライン (第6.2版). 2018. <https://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_c>
 
8) Kumada H, et al : Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection. J Gastroenterol 53 : 566-575, 2018.
 
P.178 掲載の参考文献
1) van der Meer A J, et al : Reversion of disease manifestations after HCV eradication. J Hepatol 65 : S95-S108, 2016.
PubMed
2) Ogasawara N, et al : Serial changes in liver stiffness and controlled attenuation parameter following drect-acting antiviral therapy against hepatitis C virus genotype 1b. J Med Virol 90 : 313-319, 2018.
 
3) Reig M, et al Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 65 : 719-726, 2016.
PubMed
4) Nagata H, et al : Effect of interferon-based and-free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C.　J Hepatol 67 : 933-939, 2017.
 
5) Waziry R, et al : Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy : A systematic review, meta-analyses, and meta-regression. J Hepatol 67 : 1204-1212, 2017.
PubMed
6) Kanwal F, et al : Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology 153 : 996-1005. e1, 2017.
 
7) 肝炎診療ガイドライン作成委員会 : C型肝炎治療ガイドライン (第6.2版). 2018.
Medical*Online
8) Takehara T, et al : Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis : an open-label phase 3 trial. J Gastroenterol 2018 [Epub ahead of print].
 
9) El-Sherif O, et al : Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection. Gastroenterology 154 : 2111-2121. e8, 2018.
 
10) Chen G, et al : Hepadtis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents : A systematic review and meta-analysis. Hepatology 66 : 13-26, 2017.
 
11) Mucke M M, et al : Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C : a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 3 : 172-180, 2018.
PubMed
12) Kawagishi N, et al : Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C. J Viral Hepat 24 : 1098-1106, 2017.
PubMed
13) Doi A, et al : Frequency of, and factors associated with, hepatitis B virus reactlvation in hepatitis C patients treated with all-oral direct-acting antivirals : Analysis of a Japanese prospective cohort. Hepatol Res 47 : 1438-1444, 2017.
PubMed
14) Tamori A, et al : Low incidence of hepatitis B virus reactivation and subsequent hepatitis in patients with chronic hepatitis C receiving direct-acting antiviral therapy. J Viral Hepat 25 : 608-611, 2018.
PubMed
15) Akuta N, et al : Relationships between serum asunaprevir concentration and alanine aminotransferase elevation during daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. J Med Virol 88 : 506-511, 2016.
PubMed
16) Fujii Y, et al : Drug-induced immunoallergic hepatitis during combination therapy with daclatasvir and asunaprevir. Hepatology 61 : 400-401, 2015.
PubMed
17) Maekawa S, et al : Association between alanine aminotransferase elevation and UGT1A1*6 polymorphisms in daclatasvir and asunaprevir combination therapy for chronic hepatitis C. J Gastroenterol 53 : 780-786, 2018.
PubMed
18) Toyoda H, et al : Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan. J Gastroenterol 2018 [Epub ahead of print].
 
P.188 掲載の参考文献
1) 肝炎診療ガイドライン作成委員会 : C型肝炎治療ガイドライン (第6.2版). <https://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_c>
Medical*Online
2) Kumada H, et al : Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 59 : 2083-2091, 2014.
PubMed
3) Itakura J, et al : Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure. PLoS One 11 : e0165339, 2016.
PubMed
4) Fridell R A, et al : Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans : in vitro and in vivo correlations. Hepatology 54 : 1924-1935, 2011.
PubMed
5) Krishnan P, et al : Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan. Antimicrob Agents Chemother 62 (2) : pii : e02217-17, 2018.
 
6) Karino Y, et al : Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol 58 : 646-654, 2013.
PubMed
7) Kumada H, et al : Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection. J Gastroenterol 53 : 566-575, 2018.
 
8) Izumi N, et al : Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals. Hepatol Int 12 (4) : 356-367, 2018.
 
P.196 掲載の参考文献
1) McCaughan G W, et al : Sofosbuvir and daclatasvir therapy in patients with hepatitis C-related advanced decompensated liver disease (MELD≧15). Aliment Pharmacol Ther 47 (3) : 401-411, 2018.
 
2) Chanton M, et al : Ledipasvir and Sofbsbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology 149 (3) : 649-659, 2015.
 
3) Manns M, et al : Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease : a multicentre, open-label, randomised, phase 2　trial. Lancet Infect Dis 16 (6) : 685-697, 2016.
PubMed
4) AASLD/IDSA HCV Gtlidance Panel. Hepatitis C guidance : AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62 (3) : 932-954, 2015.
PubMed
5) Curry M P, et al : Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med 373 (27) : 2618-2628, 2015.
PubMed
6) Younossi Z M, et al : Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis : an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. Lancet Gastroenterol Hepatol 1 (2) : 122-132, 2016.
 
7) Foster G R, et al : Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 64 (6) : 1224-1231, 2016.
PubMed
8) Lim J K, et al : Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. Clin Gastroenterol Hepatol 2018 [Epub ahead of print].
PubMed
9) Fernandez Carrillo C, et al : Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease : Analysis of data from the Hepa-C registry. Hepatology 65 (6) : 1810-1822, 2017.
 
10) Taniyama O, et al : Sustained virologic response after eight weeks of treatment with sofosbuvir, ledipasvir, and ribavirin in a decompensated cirrhotic patient with hepatitis C virus genotype 1b. Hepatol Res 2018 [Epub ahead of print].
 
11) Takehara T, et al : Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis : an open-label phase 3 trial. J Gastroenterol 2018 [Epub ahead of print].
 
12) Dyson J K, et al : Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. J Hepatol 64 (1) : 234-238, 2016.
PubMed
13) Verma N, et al : Sofosbuvir induced steven Johnson Syndrome in a patient with hepatitis C virus-related cirrhosis. Hepatol Commun 2 (1) : 16-20, 2017.
 
14) Welker M W, et al : Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofbsbuvir treatment. J Hepatol 64 (4) : 790-799, 2016.
PubMed
15) European Association for the Study of the Liver (EASL) : EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones. J Hepatol 65 (1) : 146-181, 2016.
 
16) Tahata Y, et al : Liver Fibrosis Is Associated With Corrected QT Prolongation During Ledipasvir/Sofosbuvir Treatment for Patients With Chronic Hepatitis C. Hepatol Commun 2 (8) : 884-892, 2018.
PubMed
17) Cox-North P, et al : Sofosbuvir-based regimens for the treatment of chronic hepatitis C in severe renal dysfunction. Hepatol Commun 1 (3) : 248-255, 2017.
PubMed
18) El-Sherif O, et al : Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection. Gastroenterology 154 (8) : 2111-2121. e8, 2018.
 
19) Cheung M C M, et al : Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 65 (4) : 741-747, 2016.
PubMed
20) Belli L S, et al : Delisting of liver transplant candidates with chronic hepatitis C after viral eradication : A European study. J Hepatol 65 (3) :　524-531, 2016.
PubMed
21) Mandorfer M, et al : Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol 65 (4) : 692-699, 2016.
PubMed
22) Afdhal N, et al : Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. J Viral Hepat 24 (10) : 823-831, 2017.
PubMed
23) Lens S, et al : Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. Gastroenterology 153 (5) : 1273-1283. e1, 2017.
 
P.205 掲載の参考文献
1) 日本肝癌研究会追跡調査委員会 : 第19回全国原発性肝癌追跡調査報告 (2006-2007). 肝臓 57 (1) : 45-73, 2016.
 
2) Kasahara A, et al : Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death. J Viral Hepat 11 (2) : 148-156, 2004.
 
3) Yoshida H, et al : Interferon Therapy Reduces the Risk for Hepatocellular Carcinoma : National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan. Ann Intern Med 131 (3) : 174-181, 1999.
PubMed
4) Kawamura Y, et al : Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patients. Am J Med 123 (10) : 951-956, 2010.
PubMed
5) Asahina Y, et al : Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology 52 (2) : 518-527, 2010.
PubMed
6) Tateyama M, et al : Alpha-fetoprotein above normal levels as a risk factor for the development of epatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol 46 (1) : 92-100, 2011.
 
7) Arase Y, et al : Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology 57 (3) : 964-973, 2013.
PubMed
8) Tada T, et al : Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection : a propensity score analysis. Liver Int 36 (6) : 817-826, 2016.
PubMed
9) Morgan R L, et al : Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma : a meta-analysis of observational studies. Ann Intern Med 158 (5) : 329-337, 2013.
 
10) Watanabe S, et al : Cancer preventive effect of pegylated interferon alpha-2b plus ribavirin in a real-life clinical setting in Japan : PERFECT interim analysis. Hepatol Res 41 (10) : 955-964, 2011.
 
11) Oze T, et al : Post-treatment levels of alpha-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy. Clin Gastroenterol Hepatol 12 (7) : 1186-1195, 2014.
PubMed
12) Lok A S, et al : Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 140 (3) : 840-849, 2011.
PubMed
13) Makiyama A, et al : Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer 101 (7) : 1616-1622, 2004.
PubMed
14) Tanaka A, et al : Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with anti-viral therapy in patients with chronic hepatitis C. World J Gastroenterol 13 (39) : 5180-5187, 2007.
 
15) Akuta N, et al : Amino acid substitu-tions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy. J Med Virol 83 (6) : 1016-1022, 2011.
 
16) Asahina Y, et al : Alpha-fetoprotein levels after interferon therapy and risk of hepatocar-cinogenesis in chronic hepatitis C. Hepatology 58 (4) : 1253-1262, 2013.
 
17) Nagaoki Y, et al : Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy : A large-scale, long-term cohort study. J Gastroenterol Hepatol 31 (5) : 1009-1015, 2016.
PubMed
18) Chang K C, et al : A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy. J Antimicrob Chemother 67 (11) : 2766-2772, 2012.
PubMed
19) Reig M, et al : Unexpected high rate of early tumor recurrence in patients with related HCC undergoing interferon-free therapy. J Hepatol 65 (4) : 719-726, 2016.
PubMed
20) Conti F, et al : Early occurrence and recurrence　of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 65 (4) : 727-733, 2016.
PubMed
21) Waziry R, et al : Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy : A systematic review, meta-analyses, and meta-regression. J Hepatol 67 (6) : 1204-1212, 2017.
PubMed
22) Innes H, et al : The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response : role of the treatment regimen. J Hepatol 68 : 646-654, 2018.
PubMed
23) Ioannou G N, et al : HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol 68 : 25-32, 2018.
 
24) Nagata H, et al : Effect of interferon-based and-free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J Hepatol 67 (5) : 933-939, 2017.
 
25) Toyoda H, et al : Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatoceilular carcinoma after eradication of hepatitis C virus in Japan. J Viral Hepat 24 (6) : 472-476, 2017.
PubMed
26) Kanwal F, et al : Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology 153 (4) : 996-1005, 2017.
PubMed
27) Toyoda H, et al : Impact of previously cured hepatocellular carcinoma (HCC) on new development of HCC after eradication of hepatitis C infection with non-interferon-based treatments. Aliment Pharmacol Ther 48 (6) : 664-670, 2018.
PubMed
28) Ooka Y, et al : Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection. Hepatol Int 2018 (in press).
 
29) Ioannou G N, et al : Development of models estimating the risk of hepatocellular carcinoma after antiviral treatmellt for hepatitis C. J Hepatol 2018 [Epub ahead of print].
 
P.208 掲載の参考文献
1) Belperio P S, et al : Hepatology 66 (1) : 27, 2017.
PubMed
2) Cheng W, et al : Clin Gastroenterol Hepatol 15 (1) : 132, 2017.
 
3) Kawagishi N, et al : J Hepatol 67 (5) : 1106, 2017.
PubMed
4) Kawagishi N, et al : J Viral Hepat 24 (12) : 1098, 2017.
PubMed
5) Balagopaj A, et al : Clin Infect Dis 61 (8) : 1307, 2015.
PubMed
6) Chen S Y, et al : J Biol Chem 278 : 591, 2003.
 

第6章 経口肝炎 ( A型, E型肝炎 )

P.214 掲載の参考文献
1) 神田達郎, 他 : A型肝炎の最近の動向. 消化器・肝臓内科 4 (2) : 2018.
 
2) 国立感染症研究所ホームページ :　<https://www.niid.go.jp/niid/ja/id/1558-disease-based/a/hepatitis/hepatitis-a/idsc/idwr-sokuhou/8185-hepa-180622.html>
 
3) Miyamura T, et al : Possible widespread presence of hepatitis A virus subgenotype IIIA in Japan : Recent trend of hepatitis A causing acute liver failure. Hepatol Res 42 (3) : 248-253, 2012.
PubMed
4) Yan J, et al : Hepatitis A, B, C and E virus markers in Chinese residing in Tokyo, Japan. Hepatol Res 42 (10) : 974-981, 2012.
 
5) Tominaga A, et al : Hepatitis A outbreak associated with a revolving sushi bar in Chiba, Japan : Application of molecular epidemiology. Hepatol Res 42 (8) : 828-834, 2012.
PubMed
6) Kanda T, et al : Direct-acting Antivirals and Host-targeting Agents against the Hepatitis A Virus. J Clin Transl Hepatol 3 (3) : 205-210, 2015.
PubMed
7) Feng Z, et al : Apathogenic picornavirus acquires an envelope by hijacking cellular mem. branes. Nature 496 (7445) : 367-371, 2013.
 
8) 高橋和明, 他 : 血中のA型肝炎ウイルス粒子には脂質膜エンベロープが存在する. 肝臓 54 (6) : 396-398, 2013.
 
9) Kanda T, et al : Suppression of hepatitis A virus genome translation and replication by siRNAs targeting the internal ribosomal entry site. Biochem Biophys Res Commun 330 (4) : 1217-1223, 2005.
PubMed
10) Kanda T, et al : Amantadine inhibits hepatitis A virus internal ribosomal entry site-mediated translation in human hepatoma cells. Biochem Biophys Res Commun 331 (2) : 621-629, 2005.
PubMed
11) Kanda T, et al : Internal ribosomal entry-site activities of clinical isolate-derived hepatitis A virus and inhibitory effects of amantadine. Hepatol Res 40 (4) : 415-423, 2010.
PubMed
12) Kanda T, et al : Analysis of 5' nontranslated region of hepatitis A viral RNA genotype I from South Korea : comparison with disease severities. PLoS One 5 (12) : e15139, 2010.
PubMed
13) Wu S, et al : Ultra-deep sequencing analysis of the hepatitis A virus 5'-untranslated region among cases of the same outbreak from a single source. Int J Med Sci 11 (1) : 60-64, 2013.
PubMed
14) Zhang L, et al : Variants in ABCB1, TGFB1, and XRCC1 genes and susceptibility to viral hepatitis A infection in Mexican Americans. Hepatology 55 (4) : 1008-1018, 2012.
PubMed
15) Long D, et al : Whole genome sequencing to identify host genetic risk factors for severe outcomes of hepatitis a virus infection. J Med Virol 86 (10) : 1661-1668, 2014.
PubMed
16) Win N N, et al : Free fatty acids or high-concentration glucose enhances hepatitis A virus replication in association with a reduction in glucose-regulated protein 78 expression. Biochem Biophys Res Commun 483 (1) : 694-699, 2017.
PubMed
17) Jiang X, et al : Glucose-regulated protein 78 is an antiviral against hepatitis A virus replication. Exp Ther Med 13 (6) : 3305-3308, 2017.
PubMed
18) Win N N, et al : Inhibitory effect of Japanese rice-koji miso extracts on hepatitis A virus replication in association with the elevation of glucose-regulated protein 78 expression. Int J Med Sci 15 (11) : 1153-1154, 2018.
PubMed
19) Yotsuyanagi H, et al : Prolonged fecal excretion of hepatitis A virus in adult patients with hepatitis A as determined by polymerase chain reaction. Hepatology 24 (1) : 10-13, 1996.
PubMed
20) 神田達郎 : A型肝炎の現状とトピックス. Med Pract 34 (5) : 787-789, 2017.
Medical*Online
21) Lin K Y, et al : Hepatitis A virus infection and hepatitis A vaccination in human immunodeficiency virus-positive patients : A review. World J Gastroenterol 23 (20) : 3589-3606, 2017.
PubMed
22) Ida S, et al : Influence of human immunodeficiency virus type 1 infection on acute hepatitis A virus infection. Clin Infect Dis 34 (3) : 379-385, 2002.
PubMed
23) Mena G, et al : Hepatitis B and A vaccination in HIV-infected adults : A review. Hum Vaccin Immunother 11 (11) : 2582-2598, 2015.
 
24) Kim M J, et al : Identification of transfusion-transmitted hepatitis A through postdonation information in Korea : results of an HAV lookback (2007-2012). Vox Sang 2018 [Epub ahead of print].
 
25) Takahashi H, et al : Molecular epidemiology of hepatitis A virus in metropolitan areas in Japan. J Gastroenterol 41 (10) : 981-986, 2006.
PubMed
26) 神田達郎, 他 : 乾燥A型肝炎ワクチン. 肝胆膵 61 (6) : 1095-1099, 2010.
Medical*Online
27) Jung Y M, et al : Atypical manifestations of hepatitis A infection : a prospective, multicenter study in Korea. J Med Virol 82 (8) : 1318-1326, 2010.
 
28) Jeong S H, et al : Hepatitis A : clinical manifestations and management. Intervirology 53 (1) : 15-19, 2010.
PubMed
29) Kim JD, et al : A Novel Model to Predict 1-Month Risk of Transplant or Death in Hepatitis A-Related Acute Liver Failure. Hepatol 2018 [Epub ahead of print].
 
P.222 掲載の参考文献
1) 安藤文英, 他 : 国内で感染し発症した散発性E型急性肝炎と思われる1邦人例. 肝臓 35 : 560-565, 1994.
 
2) Schlauder G G, et al : The sequence and phylogenetic analysis of a novel hepatitis E virus isolated from a patient with acute hepatitis reported in the United States. J Gen Virol 79 : 447-456, 1998.
PubMed
3) Kwo P Y, et al : Acute hepatitis E by a new isolate acquired in the United States. Mayo Clin Proc 72 : 1133-1136, 1997.
PubMed
4) Takahashi K, et al : Full-genome nucleotide sequence of a hepatitis E virus strain that may be indigenous to Japan. Virology 287 : 9-12, 2001.
PubMed
5) Kamar N, et al : Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 358 : 811-817, 2008.
PubMed
6) Kamar N, et al : Hepatitis E virus-related cirrhosis in kidney-and kidney-pancreas-transplant recipients. Am J Transplant 8 : 1744-1748, 2008.
PubMed
7) Miyashita K, et al : Three cases of acute or fulminant hepatitis E caused by ingestion of pork meat and entrails in Hokkaido, Japan : Zoonotic food-borne transmission of hepatitis E virus and public health concerns. Hepatol Res 42 : 870-878, 2012.
 
8) Tamada Y, et al : Consumption of wild boar linked to cases of hepatitis E. J Hepatology 40 : 869-870, 2004.
 
9) Tei S, et al : Zoonotic transmission of hepatitis E virus from deer to human beings. Lancet 362 : 371-373, 2003.
PubMed
10) Ishida S, et al : Detection and molecular characterization of hepatitis E virus in clinical, environmental and putative animal sources. Arch Virol 157 : 2363-2368, 2012.
PubMed
11) Li T C, et al : Detection of hepatitis E virus RNA from the bivalve Yamato-Shijimi (Corbicula japonica) in Japan. Am J Trop Med Hyg 76 : 170-172, 2007.
PubMed
12) Gao S, et al : Surveillance of Hepatitis E Virus Contamination in Shellfish in China. Int J Environ Res Public Health 12 : 2026-2036, 2015.
PubMed
13) Arankalle V A, et al : Human and swine hepatitis Eviruses from Western India belong to different genotypes. J Hepatol 36 : 417-425, 2002.
 
14) 阿部敏紀, 他 : 本邦に於けるE型肝炎ウイルス感染の統計学的・疫学的・ウイルス学的特徴 : 全国集計254例に基づく解析. 肝臓 47 : 384-391, 2006.
 
15) 国立感染症研究所HP. IDWR速報データ
 
16) Takeda H, et al : Anationwide survey for prevakence of hepatitis E virus antibody in qualified blood donors in Japan. Vox San 99 : 307-313, 2010.
 
17) Matsubayashi K, et al : Acase of transfusion-transmitted hepatitis E caused by blood from a donor infected with hepatitis E virus via zoonotic food-bome route. Transfusion 48 : 1368-1375, 2008.
 
18) Matsui T, et al : Rare case of transfusion-transmitted hepatitis E from the blood of a donor infected with the hepatitis E virus genotype 3 indigenous to Japan : Viral dynamics from onset to recovery. Hepatol Res 45 : 698-704, 2015.
PubMed
19) Miyoshi M, et al : Chronic Hepatitis E Infection in a Persistently Immunosuppressed Patient Unable to Be Eliminated after Ribavirin Therapy. Intern Med 55 : 2811-2817, 2016.
 
20) Lhomme S, et al : Mutation in the Hepatitis E Virus Polymerase and Outcome of Ribavirin Therapy. Antimicrob Agents Chemother 60 : 1608-1614, 2015.
PubMed

第7章 肝疾患診療と行政, 病診連携

P.231 掲載の参考文献
1) 厚生労働省ホームページ「肝炎総合対策の推進」 より <http://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou09/pdf/hourei-27.pdf>
 
2) Oza N, et al : Current activities and future directions of comprehensive hepatitis control measures in Japan : The supportive role of the Hepatitis Information Center in building a solid foundation. Hepatol Res 47 : 487-496, 2017.
PubMed
3) 厚生労働省ホームページ「肝炎総合対策の推進」より <http://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou09/pdf/150325-01.pdf>
 
4) 厚生労働省ホームページ「肝炎総合対策の推進」より <http://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou09/080328_josei.html>
 
5) 厚生労働省ホームページより <https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/hukushi_kaigo/shougaishahukushi/shougaishatechou/index.html>
 
P.236 掲載の参考文献
1) 都道府県における肝炎検査後肝疾患診療体制に関するガイドライン 全国C型肝炎診療懇談会報告書 (平成19年1月26日). <https://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou09/03.html>
 
2) 肝疾患診療体制の整備について (通知, 健発第0419001号平成19年4月19日).　<https://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou09/pdf/hourei-24.pdf>
 
3) 肝炎対策基本法 (平成21年12月4日法律九十七号, 平成22年1月1日施行, 平成25年12月13日改正). <https://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou09/hourei_01.html>
 
4) 肝炎対策の推進に関する基本的な指針 (平成23年5月16日策定, 平成28年6月30日改正). <https://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou09/pdf/hourei-27.pdf>
 
5) 国立国際医療研究センター肝炎情報センターホームページ. <www.kanen.ncgm.go.jp/index.htmi>
 
P.243 掲載の参考文献
1) Tanaka J, et al : Trends in the total numbers of HBV and HCV carriers in Japan from 2000 to 2011. J Viral Hepat 25 : 363-372, 2018.
PubMed
2) 白木和夫 : わが国におけるB型肝炎母子感染防止の経緯とuniversal vaccinationの必要性について. 小児感染免疫 21 (2) : 149-157, 2009.
 
3) Okada K, et al : Hepatitis B surface antigen in the serum of infants after deliver from asymptomatic carrier mothers. J Pediatr 87 (3) : 360-363, 1975.
PubMed
4) Okada K, et al : eantigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants. N Engl J Med 294 (14) : 746-749, 1976.
 
5) Shiraki K, et al : Acute hepatitis B in infants born tocarrier mothers with the antibody to hepatitis Beantigen. J Pediatr 97 (5) : 768-770, 1980.
 
6) 白木和夫, 他 : B型肝炎ウイルスの垂直感染-そのnatural historyと予防. 医のあゆみ 118 : 536-545, 1981.
 
7) Shiraki K : Vertical transmission of hepatitis B virus and its prevention in Japan. In : Viral Hepatitis and Liver Disease (Nishioka K, et al, eds) p530-532. Springer-Verlag, Tokyo, 1994.
 
8) 白木和夫 : B型肝炎母子感染防止対策の追跡調査および効果判定に関する研究. 厚生省心身障害研究「小児の心身障害・疾患の予防と治療に関する研究」 (主任研究者 : 柳澤信義) 分担研究 平成8年度研究報告書, 1997.
 
9) Emini E A, et al : Production and immunological analysis recombinant hepatitis B vaccine. J Infect 13 (Suppl. A) : 3-9, 1986.
 
10) Hamada-Tsutsumi S, et al : Validation of cross-genotype neutralization by hepatitis B virus-specific monoclonal antibodies by in vitro and in vivo infection. PLoS ONE 10 (2) : e0118062, 2015.
PubMed
11) 小松陽樹, 他 : Genotype AのB型肝炎ウイルスキャリア妊婦に対するgenotype C由来の抗原を用いたHBワクチンの母子感染予防効果. 肝臓 56 (12) : 675-677, 2015.
 
12) 乾あやの, 他 : B型肝炎母子感染防止不成功例の解析. 肝臓 51 (8) : 457-459, 2010.
 
13) <http://www.med-safe.jp/contents/info/index.html>
 
14) Wen W-H, et al : Mother-to-infant transmission of hepatitis B virus infection : Significance of maternal viral load and strategies for intervention. J Hepatol 59 : 24-30, 2013.
PubMed
15) Xu W M, et al : Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection : a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat 16 (2) : 94-103, 2009.
PubMed
16) Wu Q, et al : Telbivudine prevents vertical transmission of hepatitis B virus from women with high viral loads : a prospective long-term study. Clin Gastrienterol Hepatol 13 : 1170-1175, 2015.
PubMed
17) Greenup A-J, et al : Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol 61 (3) : 502-507, 2014.
PubMed
18) Li W, et al : Efficacy and safety of tenofovir in preventing mother-to-infant transmission of hepatitis B virus : a meta-analysis based on 6 studies from China and 3 studies from other countries. BMC Gastroenterol 18 (1) : 121, 2018.
PubMed
19) Wakano Y, et al : Antiviral therapy for hepatitis B virus during second pregnancies. J Obstet Gynaecol Res 44 (3) : 566-569, 2018.
PubMed

書評

最近チェックした商品履歴

Loading...